Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in type 2 diabetes patients: 4‐year data

ConclusionsIn patients completing 4 years of treatment, dapagliflozin was well tolerated and associated with sustained glycaemic efficacy and greater reductions in body weight and SBP versus glipizide.

Source: Diabetes, Obesity and Metabolism - March 1, 2015 Category: Endocrinology Authors: Stefano Del Prato, Michael Nauck, Santiago Durán‐Garcia, Laura Maffei, Katja Rohwedder, Anett Theuerkauf, Shamik Parikh Tags: ORIGINAL ARTICLE Source Type: research